Advertisement
Advertisement
U.S. markets open in 9 hours 5 minutes
Advertisement
Advertisement
Advertisement
Advertisement

BuzzFeed, Inc. (BZFD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.6200+0.0800 (+5.19%)
At close: 04:00PM EDT
1.6500 +0.03 (+1.85%)
After hours: 07:35PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Intermediate-term KST

Intermediate-term KST

Previous Close1.5400
Open1.5400
Bid1.5800 x 800
Ask1.6500 x 1000
Day's Range1.5300 - 1.6300
52 Week Range1.5000 - 14.7700
Volume122,353
Avg. Volume369,760
Market Cap219.447M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.5990
Earnings DateMay 16, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
-2% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BZFD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BuzzFeed, Inc.
    Analyst Report: 23andMe Holding Co.23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.
    Rating
    Fair Value
    Economic Moat
    18 days agoMorningstar
View more
Advertisement
Advertisement